


REMARKS

The Amendment

Entry of this amendment is respectfully requested. No new matter is added by the amendment, because the new claims find support in the application as filed. In particular, the new claims remove multiple dependencies.

Claims 1-20 are in this application, no claims having been added or canceled, and Claims 3-10, 13, 14, and 16 having been amended by this amendment. Entry of the amendment and allowance of the claims are requested.

Respectfully submitted,



Derek P. Freyberg
Attorney for Applicants
Reg. No. 29,250

Customer No.: 25213

Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7014
December 19, 2001

Claims as amended showing amendments -
additions in bold, deletions in bold brackets

3. (Amended) The purified arabinogalactan composition of Claim 1 [or 2] that is isolated from *Astragalus membranaceus* plants grown in Inner Mongolia or Shanxi province, Peoples' Republic of China[, especially the former].

4. (Amended) The purified arabinogalactan composition of [any of Claims] **Claim** 1 [to 3] where the *Astragalus membranaceus* plants are two-year old *Astragalus membranaceus* plants.

5. (Amended) The purified arabinogalactan composition of [any of Claims] **Claim** 1 [to 4] having a weight average molecular weight of 20 kiloDaltons to 60 kiloDaltons.

6. (Amended) The purified arabinogalactan composition of [any of Claims] **Claim** 1 [to 5] having an arabinose/galactose ratio of at least 1.5.

7. (Amended) The purified arabinogalactan composition of [any of Claims] **Claim** 1 [to 6] having an endotoxin content of not more than 1.0 EU/mg.

8. (Amended) An arabinogalactan protein composition, having a weight average molecular weight of at least 100 kiloDaltons, isolated from a purified arabinogalactan composition of [any of Claims] **Claim** 1 [to 7].

9. (Amended) An aqueous intravenously injectable arabinogalactan formulation comprising:

(a) a therapeutically effective amount of the purified arabinogalactan composition of [any of Claims] **Claim** 1 [to 7 or

the arabinogalactan protein composition of Claim 8]; and
(b) an aqueous intravenously injectable excipient.

10. (Amended) A method of treating a disease state in a mammal capable of treatment by administration of the purified arabinogalactan composition of [any of Claims] **Claim 1** [to 7 or the arabinogalactan protein composition of Claim 8], comprising intravenously administering to the mammal an effective amount of the purified arabinogalactan composition of [any of Claims] **Claim 1** [to 7 or the arabinogalactan protein composition of Claim 8, or the aqueous intravenously injectable arabinogalactan formulation of Claim 9].

13. (Amended) The method of [any one of Claims] **Claim 10** [to 12] where the mammal is a human.

14. (Amended) The method of Claim 12 [or 13] where the mammal is suffering from bone marrow suppression.

16. (Amended) The method of [any one of Claims] **Claim 10** [to 15] further comprising the administration of at least one other therapeutic agent.